

Influenza A Virus, A/Brisbane/10/2007 (H3N2), BPL-Inactivated

Catalog No. NR-19321

For research use only. Not for use in humans.

Contributor:

Alexander Klimov, Ph.D., Chief, Viral Surveillance and Diagnostic Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Manufacturer:

BEI Resources

Product Description:

NR-19321 is a preparation of influenza A virus, A/Brisbane/10/2007 (H3N2) that has been inactivated with beta-propiolactone (BPL). A/Brisbane/10/2007 (H3N2)-like viruses were used as the influenza A (H3N2) component of trivalent vaccines worldwide from 2008 to 2010.^{1,2} The inactivated virus preparation was diluted 1:500 in DPBS to make NR-19321. NR-19321 has been qualified for quantitative PCR.

Influenza A virus, A/Brisbane/10/2007 (H3N2) was isolated from a human in Brisbane, Australia on February 6, 2007. Sequence information is available for influenza A virus, A/Brisbane/10/2007 (H3N2) at the [Bacterial and Viral Bioinformatics Resource Center](#).

Material Provided:

Each vial contains approximately 100 µL of BPL-inactivated influenza A virus, A/Brisbane/10/2007 (H3N2).

Packaging/Storage:

NR-19321 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read “The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Brisbane/10/2007 (H3N2), BPL-Inactivated, NR-19321.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. This product is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Fiore, A. E., et al. “Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.” [MMWR Recomm. Rep. 57 \(2008\): 1-60](#). PubMed: 18685555.
2. Fiore, A. E., et al. “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.” [MMWR Recomm. Rep. 58 \(2009\): 1-52](#). PubMed: 19644442.

ATCC® is a trademark of the American Type Culture Collection.

